

Yin-Xin Wang, Si-Qi Geng, Jia-Rui Qin, Wen-Li Zhang* and Qi-Di Zhong

Crystal structure of dimethyl 1,4,6,9-tetraphenylhexahydro-3*H*-2,7,3,5-(epimethanetriyliminomethanetriyl)cyclopenta [*b*]pyridine-3,7(2*H*)-dicarboxylate, C₃₈H₃₄N₂O₄




Table 1: Data collection and handling.

Crystal:	Colourless block
Size:	0.18 × 0.16 × 0.15 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.09 mm ⁻¹
Diffractometer, scan mode:	Bruker APEX-II, φ and ω
$\theta_{\max}$, completeness:	27.5°, 99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	9220, 6596, 0.016
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2\sigma(I_{\text{obs}})$, 5121
$N(\text{param})_{\text{refined}}$:	399
Programs:	Bruker [1], SHELX [2, 3]

The molecular structure is shown in Figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Source of material

Preparation of the 1,4-diaryl-1,4-dihydropyridine-3-carboxylic acid photoreactive raw materials was performed by a literature method [4]: aniline (0.5 mmol), ethyl propiolate (0.5 mmol) and 4-methylcinnamaldehyde (0.5 mmol); piperazine (0.25 mmol) and *p*-toluenesulfonic acid (0.02 mmol) used as catalysts, and 20 mL of 1,2-dichloroethane (20 mL) were mixed. The mixture was heated to reflux for 12 h to obtain 1-phenyl-4-(4-methyl-phenyl)-1,4-dihydroethylpyridine-3-carboxylate. The 1-phenyl-4-(4-methyl-phenyl)-1,4-dihydroethylpyridine-3-carboxylate (0.5 mmol) obtained in the first step was placed near a blue LED (365 nm) for a photo-reaction for 3 h [5]. The product was obtained by column chromatography eluting with petroleum ether and ethyl acetate 10:1. The resulting solution was evaporated to get some colorless crystals.

Experimental details

All hydrogen atoms were placed in the calculated positions.

<https://doi.org/10.1515/ncrs-2022-0038>

Received January 21, 2022; accepted March 11, 2022;
published online April 4, 2022

Abstract

C₃₈H₃₄N₂O₄, triclinic, $P\bar{1}$ (no. 2), $a = 11.1158(19)$ Å, $b = 11.302(2)$ Å, $c = 12.634(2)$ Å, $\alpha = 72.109(2)^\circ$, $\beta = 77.410(2)^\circ$, $\gamma = 82.648(3)^\circ$, $V = 1362.4(5)$ Å³, $Z = 2$, $R_{\text{gt}}(F) = 0.0473$, $wR_{\text{ref}}(F^2) = 0.1738$, $T = 296$ K.

CCDC no.: 2143423

*Corresponding author: Wen-Li Zhang, Comprehensive Testing and Analytical Center, North China University of Science and Technology, 063210 Caofeidian District, Tangshan, P. R. China, E-mail: dianj@163.com

Yin-Xin Wang, Jia-Rui Qin and Qi-Di Zhong, School of Pharmacy, North China University of Science and Technology, 063210 Caofeidian District, Tangshan, P. R. China. <https://orcid.org/0000-0002-9036-6078> (Y.-X. Wang)

Si-Qi Geng, School of Clinical Medicine, North China University of Science and Technology, 063210 Caofeidian District, Tangshan, P. R. China

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	<i>U</i> _{iso} */ <i>U</i> _{eq}
O1	0.43060 (10)	0.33694 (12)	0.25888 (11)	0.0486 (3)
O2	0.41268 (10)	0.44641 (12)	0.38234 (10)	0.0492 (3)
O3	1.07900 (12)	0.56210 (16)	0.16452 (12)	0.0692 (5)
O4	0.98680 (11)	0.54287 (13)	0.34253 (10)	0.0536 (4)
N1	0.71403 (11)	0.63020 (11)	0.21005 (10)	0.0307 (3)
N2	0.74671 (10)	0.30828 (11)	0.35398 (10)	0.0302 (3)
C1	1.04233 (16)	0.17146 (17)	0.15810 (18)	0.0514 (5)
H1	1.030837	0.194130	0.083546	0.062*
C2	1.11000 (19)	0.06188 (19)	0.1988 (2)	0.0656 (6)
H2	1.142688	0.011300	0.152270	0.079*
C3	1.12887 (18)	0.0278 (2)	0.3081 (2)	0.0717 (7)
H3	1.174450	−0.045941	0.336023	0.086*
C4	1.07979 (17)	0.1037 (2)	0.3770 (2)	0.0623 (6)
H4	1.092537	0.080719	0.451179	0.075*
C5	1.01157 (15)	0.21393 (18)	0.33553 (16)	0.0491 (4)
H5	0.979509	0.264685	0.382042	0.059*
C6	0.99089 (13)	0.24892 (15)	0.22523 (14)	0.0396 (4)
C7	0.92002 (13)	0.36777 (14)	0.17107 (12)	0.0348 (3)
H7	0.972447	0.405381	0.097995	0.042*
C8	0.88342 (12)	0.47221 (14)	0.22896 (12)	0.0319 (3)
C9	0.81264 (13)	0.57168 (14)	0.14110 (11)	0.0324 (3)
H9	0.867530	0.632637	0.085875	0.039*
C10	0.75604 (13)	0.49305 (15)	0.08349 (12)	0.0345 (3)
H10	0.785948	0.514756	0.001409	0.041*
C11	0.79379 (13)	0.35783 (14)	0.14407 (12)	0.0337 (3)
H11	0.798609	0.302025	0.097085	0.040*
C12	0.69248 (12)	0.32287 (13)	0.25424 (11)	0.0306 (3)
H12	0.650261	0.249372	0.260418	0.037*
C13	0.60202 (12)	0.44331 (13)	0.24500 (11)	0.0299 (3)
C14	0.66390 (12)	0.52218 (13)	0.29893 (11)	0.0284 (3)
H14	0.607939	0.544653	0.362330	0.034*
C15	0.77867 (12)	0.43449 (13)	0.33603 (11)	0.0289 (3)
H15	0.800076	0.445776	0.403415	0.035*
C16	0.74712 (13)	0.73169 (13)	0.23860 (12)	0.0322 (3)
C17	0.73080 (15)	0.73823 (16)	0.34895 (14)	0.0416 (4)
H17	0.696713	0.673274	0.409280	0.050*
C18	0.76563 (18)	0.84230 (18)	0.36893 (16)	0.0548 (5)
H18	0.753605	0.846053	0.443050	0.066*
C19	0.81710 (17)	0.93929 (18)	0.28242 (17)	0.0558 (5)
H19	0.841967	1.007025	0.297458	0.067*
C20	0.83132 (18)	0.93455 (17)	0.17267 (17)	0.0546 (5)
H20	0.865425	1.000005	0.112908	0.065*
C21	0.79526 (16)	0.83324 (16)	0.15077 (14)	0.0454 (4)
H21	0.803199	0.832644	0.076115	0.054*
C22	0.61473 (13)	0.50144 (14)	0.11513 (12)	0.0337 (3)
H22	0.585652	0.441173	0.086356	0.040*
C23	0.54602 (15)	0.62529 (15)	0.07012 (13)	0.0390 (4)
C24	0.60661 (18)	0.72672 (19)	−0.00652 (17)	0.0575 (5)
H24	0.691986	0.719685	−0.029116	0.069*
C25	0.5418 (2)	0.8377 (2)	−0.0495 (2)	0.0786 (7)
H25	0.584379	0.904547	−0.099898	0.094*
C26	0.4155 (2)	0.8509 (2)	−0.0191 (2)	0.0747 (7)
H26	0.372717	0.926176	−0.047961	0.090*
C27	0.3534 (2)	0.7514 (2)	0.05451 (18)	0.0615 (5)
H27	0.267785	0.758896	0.075170	0.074*

Table 2: (continued)

Atom	x	y	z	<i>U</i> _{iso} */ <i>U</i> _{eq}
C28	0.41778 (16)	0.63963 (18)	0.09822 (14)	0.0470 (4)
H28	0.374321	0.572757	0.147426	0.056*
C29	0.68045 (12)	0.24302 (13)	0.46162 (12)	0.0292 (3)
C30	0.65222 (14)	0.29058 (15)	0.55398 (13)	0.0376 (3)
H30	0.675482	0.369469	0.546073	0.045*
C31	0.58983 (16)	0.22175 (18)	0.65769 (14)	0.0476 (4)
H31	0.572065	0.254901	0.718665	0.057*
C32	0.55378 (16)	0.10502 (18)	0.67175 (15)	0.0500 (4)
H32	0.510939	0.059688	0.741309	0.060*
C33	0.58199 (16)	0.05666 (16)	0.58164 (16)	0.0488 (4)
H33	0.558509	−0.022423	0.590529	0.059*
C34	0.64494 (15)	0.12373 (15)	0.47752 (14)	0.0406 (4)
H34	0.663776	0.088962	0.417553	0.049*
C35	0.30507 (16)	0.3035 (2)	0.30004 (18)	0.0573 (5)
H35A	0.250371	0.373478	0.271723	0.086*
H35B	0.288198	0.279568	0.381335	0.086*
H35C	0.292657	0.234958	0.274590	0.086*
C36	0.47204 (13)	0.41176 (14)	0.30550 (12)	0.0328 (3)
C37	1.0814 (2)	0.6115 (3)	0.3553 (2)	0.0775 (7)
H37A	1.160365	0.566957	0.343338	0.116*
H37B	1.063779	0.620733	0.430278	0.116*
H37C	1.082978	0.692274	0.300708	0.116*
C38	0.99411 (14)	0.52876 (15)	0.24132 (13)	0.0377 (3)

Comment

Cage dimer 4-aryl-1,4-dihydropyridines have a wide range of biological activities, such as anti-HIV and as an anti-multidrug resistance modulator [6–8]. The caged dimeric compound similar to the title compound has also been reported, which is obtained by a dimerization by photoreaction. However, the two pyridine rings in the title compound present a special angle, which may be of interest for the study of new functional caged compounds.

In the molecules forming the title crystal structure, the tricyclic structure formed by oxazinoquinoline structure is not in one plane. The dihedral angle of the phenyl ring formed by C23–28 and the phenyl ring formed by C6–C1 is 57°. The dihedral angle between the phenyl ring formed by C16–18 and the phenyl ring formed by C29–34 is 33.322 Å, close to a right angle. Several important bond angle data are involved as follows C2–C1–C6 = 121.9(2) Å, C36–O1–C35 = 117.56(13) Å, C16–N1–C14 = 120.10(11) Å. The bond lengths and angles are in the expected ranges [9, 10].

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This work is supported by The Project Supported by Hebei Provincial Natural Science Foundation of China (C2020209081).

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. BRUKER. SAINT. Version 8.23B; Bruker AXS Inc.: Madison, Wisconsin, USA, 2013.
2. Sheldrick G. M. Crystal structure refinement with SHELXL. *Acta Crystallogr.* 2015, *C71*, 3–8.
3. Sheldrick G. M. A short history of SHELX. *Acta Crystallogr.* 2008, *A64*, 112–122.
4. Wan J. P., Lin Y. F., Jing Y. F. Selectivity tunable divergent synthesis of 1,4- and 1,2-dihydropyridines via three-component reactions. *Tetrahedron* 2014, *70*, 7874–7880.
5. Hilgeroth A., Baumeister U., Heinemann F. W. Solution dimerization of 4-aryl-1,4-dihydropyridines. *Eur. J. Org. Chem.* 2000, *2000*, 245–249.
6. Hilgeroth A., Langner A. First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor *N*-benzyl 4-aryl-1,4-dihydropyridine H17: biotransformation and toxicity on Hep G2 cells. *Arch. Pharm.* 2000, *333*, 32–34.
7. Hilgeroth A., Billich A. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors. *Arch. Pharm.* 1999, *332*, 3–5.
8. Coburger C., Wollmann J., Krug M., Baumert C., Seifert M., Molnar J., Lage H., Hilgeroth A. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. *Bioorg. Med. Chem.* 2010, *18*, 4983–4990.
9. Hilgeroth A., Baumeister U. The first functionalized 6,12-diazatetrakisomocubanes. *Angew. Chem. Int. Ed.* 2000, *39*, 576–578.
10. Wang X., Zhang D., Zhuang P., Zhang Y., Xu J. Crystal structure of 3,10-bis(4-chlorophenyl)-6,12-dibenzyl-2,9-acetyl-6,12-diazapentacyclo [6.3.1.02,7.04,11.05,9]-dodecane, $C_{40}H_{36}Cl_2N_2O_2$. *Z. Kristallogr. N. Cryst. Struct.* 2020, *235*, 587–588.